We are live on ! Find out more
RNAC icon

Cartesian Therapeutics
RNAC

64 hedge funds and large institutions have $110M invested in Cartesian Therapeutics in 2024 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 21 increasing their positions, 10 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

110% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 10

29% more capital invested

Capital invested by funds: $85.6M → $110M (+$24.8M)

23% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 13

10.93% more ownership

Funds ownership: 17.82% → 28.75% (+11%)

5% more funds holding

Funds holding: 61 → 64 (+3)

Holders
64
Holders Change
+3
Holders Change %
+4.92%
% of All Funds
0.92%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
16
Increased
21
Reduced
10
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$36.6M
2
Citadel Advisors
Citadel Advisors
Florida
+$5.87M
3
MB
MPM BioImpact
Massachusetts
+$5.78M
4
GPP
Great Point Partners
Connecticut
+$3.12M
5
YU
Yale University
Connecticut
+$1.56M

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$8.23M
2
IC
Ikarian Capital
Texas
-$2.97M
3
LGM
Logos Global Management
California
-$2.43M
4
BFM
Boothbay Fund Management
New York
-$844K
5
Marshall Wace
Marshall Wace
United Kingdom
-$811K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$46M +$36.6M +2,341,054 +458%
MB
2
MPM BioImpact
Massachusetts
$10.1M +$5.78M +369,727 +142%
SL
3
Siren LLC
Connecticut
$9.22M +$8.94M +572,236 New
BlackRock
4
BlackRock
New York
$6.83M +$248K +15,870 +4%
Citadel Advisors
5
Citadel Advisors
Florida
$5.76M +$5.87M +375,767 New
JP Morgan Chase
6
JP Morgan Chase
New York
$4.98M +$42K +2,688 +0.9%
Vanguard Group
7
Vanguard Group
Pennsylvania
$3.92M +$100K +6,432 +3%
GPP
8
Great Point Partners
Connecticut
$3.22M +$3.12M +200,000 New
EAM
9
Erste Asset Management
Austria
$2.8M +$802K +51,333 +42%
State Street
10
State Street
Massachusetts
$2.54M +$59.8K +3,830 +2%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$2.19M +$42.8K +2,737 +2%
YU
12
Yale University
Connecticut
$1.61M +$1.56M +100,000 New
AC
13
Armistice Capital
New York
$1.59M +$1.54M +98,565 New
6CM
14
683 Capital Management
New York
$1.22M +$1.18M +75,431 New
Northern Trust
15
Northern Trust
Illinois
$1.02M +$503K +32,191 +104%
IC
16
Ikarian Capital
Texas
$841K -$2.97M -190,177 -78%
SSA
17
Schonfeld Strategic Advisors
New York
$798K +$781K +50,000 New
Balyasny Asset Management
18
Balyasny Asset Management
Illinois
$798K +$773K +49,497 New
FCH
19
Freestone Capital Holdings
Washington
$418K +$280K +17,921 +224%
N
20
Nuveen
North Carolina
$390K -$165K -10,540 -30%
DFG
21
Delphi Financial Group
Delaware
$355K – – –
Morgan Stanley
22
Morgan Stanley
New York
$355K +$231K +14,764 +204%
Charles Schwab
23
Charles Schwab
California
$307K – – –
LSAG
24
Lake Street Advisors Group
New Hampshire
$255K -$247K -15,822 -50%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$243K -$75.2K -4,814 -24%
1
2 3

RNAC Hedge Fund Activity: Q3 2024 in Review

64 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q3 2024, worth a combined $110M — up 29% from $85.6M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new RNAC positions and 13 closed out — a net gain of 3 holders — while 21 added to existing stakes and 10 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $36.6M. The largest seller was Artal Group, exiting entirely with an estimated $8.23M sold.

  • 64 institutional investors held Cartesian Therapeutics (RNAC) as of Q3 2024, up from 61 in Q2 2024.
  • Funds reported $110M of Cartesian Therapeutics stock for Q3 2024, up 29% quarter-over-quarter.
  • 16 funds opened new Cartesian Therapeutics positions in Q3 2024 and 13 closed out, a net change of +3 holders.
  • The largest Cartesian Therapeutics buyer in Q3 2024 was Fidelity Investments, an estimated $36.6M added.
  • The largest Cartesian Therapeutics seller in Q3 2024 was Artal Group, an estimated $8.23M sold.

Based on aggregated 13F filings for Q3 2024.